prikaz prve stranice dokumenta Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates
  Preuzmi
PDF 276.81 KB
Znanstveni rad - Izvorni znanstveni rad
Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates
Endocrine Research, 35 (2010), 4; 165-173. https://doi.org/10.3109/07435800.2010.505218
Kaštelan, Darko; Vlak, Tonko; Lozo, Petar; Gradišer, Marina; Mijić, Šime; Nikolić, Tatjana; Miškić, Blaženka; Car, Dolores; Tajsić, Gordana; Dušek, Tina; Jajić, Zrinka; Grubišić, Frane; Poljičanin, Tamara; Bakula, Miro; Džubur, Fedja; Strižak-Ujević, Matilda; Kadojić, Mira; Radman, Maja; Vugrinec, Maja; Kušter, Željka; Pekez, Marijeta; Radović, Endi; Labar, Ljubica; Crnčević-Orlić, Željka; Koršić, Mirko Više autora...

Citirajte ovaj rad

Kaštelan, D., Vlak, T., Lozo, P., Gradišer, M., Mijić, Š., Nikolić, T. ... Koršić, M. (2010). Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates. Endocrine Research, 35. (4), 165-173. doi: 10.3109/07435800.2010.505218

Kaštelan, Darko, et al. "Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates." Endocrine Research, vol. 35, br. 4, 2010, str. 165-173. https://doi.org/10.3109/07435800.2010.505218

Kaštelan, Darko, Tonko Vlak, Petar Lozo, Marina Gradišer, Šime Mijić, Tatjana Nikolić, Blaženka Miškić, et al. "Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates." Endocrine Research 35, br. 4 (2010): 165-173. https://doi.org/10.3109/07435800.2010.505218

Kaštelan, D., et al. (2010) 'Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates', Endocrine Research, 35(4), str. 165-173. doi: 10.3109/07435800.2010.505218

Kaštelan D, Vlak T, Lozo P, Gradišer M, Mijić Š, Nikolić T, i sur.. Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates. Endocrine Research [Internet]. 2010. [pristupljeno 08.11.2024.];35(4):165-173. doi: 10.3109/07435800.2010.505218

D. Kaštelan, et al., "Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates", Endocrine Research, vol. 35, br. 4, str. 165-173, 2010. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:106965. [Citirano: 08.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:106965
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates
AutorDarko Kaštelan
AutorTonko Vlak
AutorPetar Lozo
AutorMarina Gradišer
AutorŠime Mijić
AutorTatjana Nikolić
AutorBlaženka Miškić
AutorDolores Car
AutorGordana Tajsić
AutorTina Dušek
AutorZrinka Jajić
AutorFrane Grubišić
AutorTamara Poljičanin
AutorMiro Bakula
AutorFedja Džubur
AutorMatilda Strižak-Ujević
AutorMira Kadojić
AutorMaja Radman
AutorMaja Vugrinec
AutorŽeljka Kušter
AutorMarijeta Pekez
AutorEndi Radović
AutorLjubica Labar
AutorŽeljka Crnčević-Orlić
AutorMirko Koršić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
OBJECTIVE: The present study was designed to assess the effect of monthly ibandronate on health-related quality of life (HR-QoL) in patients with postmenopausal osteoporosis previously treated with weekly bisphosphonates. ----- METHODS: HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires. ----- RESULTS: The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates. ----- CONCLUSION: The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaEndocrine Research
Brojčani podacivol. 35, br. 4, str. 165-173
p-ISSN0743-5800
DOIhttps://doi.org/10.3109/07435800.2010.505218
URN:NBNurn:nbn:hr:105:106965
Datum objave publikacije2010
URL dokumentahttps://doi.org/10.3109/07435800.2010.505218
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-27 19:10:37